New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
Related to this article
FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
Review news in psychiatry from the last week.
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Adult ADHD Guidelines: What Resources Are Coming Soon
2
Lessons From Psychedelics on Receptor Binding and Subsequent Functional Activity
3
A Schizophrenia Case Study: Persistent Symptoms Beyond Hospitalization
4
Reframing Binge Eating Disorder Through Circuit-Level Neuroscience
5